JIANGSU WUZHONG PHARMACEUTICAL DEVELOPMENT CO., LTD. Financials JiangSu WuZhong Pharmaceutical Development Co., Ltd.
Equities
600200
CNE000000YP4
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.23 CNY | +2.65% |
|
+6.24% | +36.62% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,791 | 6,038 | 5,390 | 5,791 | 7,911 | - | - |
| Enterprise Value (EV) 1 | 3,791 | 6,038 | 5,390 | 5,791 | 7,911 | 7,911 | 7,911 |
| P/E ratio | -7.57 x | 286 x | -71.5 x | -81.4 x | 58.3 x | 39 x | 22 x |
| Yield | - | - | - | - | 0.45% | 0.71% | - |
| Capitalization / Revenue | - | - | 2.66 x | 2.59 x | 2.83 x | 2.46 x | 1.99 x |
| EV / Revenue | - | - | 2.66 x | 2.59 x | 2.83 x | 2.46 x | 1.99 x |
| EV / EBITDA | - | - | 165 x | -226 x | 31.5 x | 20.5 x | 14.4 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | 3.02 x | 3.36 x | 4.31 x | 3.86 x | 3.65 x |
| Nbr of stocks (in thousands) | 704,560 | 704,560 | 704,560 | 704,457 | 704,457 | - | - |
| Reference price 2 | 5.380 | 8.570 | 7.650 | 8.220 | 11.23 | 11.23 | 11.23 |
| Announcement Date | 21-04-28 | 22-04-26 | 23-04-26 | 24-04-24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 2,026 | 2,240 | 2,799 | 3,221 | 3,971 |
| EBITDA 1 | - | - | 32.69 | -25.62 | 251.3 | 385 | 550 |
| EBIT 1 | - | - | -75.14 | -72.16 | 138.7 | 256 | 417 |
| Operating Margin | - | - | -3.71% | -3.22% | 4.95% | 7.95% | 10.5% |
| Earnings before Tax (EBT) 1 | - | - | -75.4 | -71.19 | 140.3 | 256.2 | 420 |
| Net income 1 | -506.4 | 22.72 | -76.2 | -71.95 | 135 | 206.6 | 366 |
| Net margin | - | - | -3.76% | -3.21% | 4.82% | 6.42% | 9.22% |
| EPS 2 | -0.7110 | 0.0300 | -0.1070 | -0.1010 | 0.1925 | 0.2880 | 0.5100 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | 0.0500 | 0.0800 | - |
| Announcement Date | 21-04-28 | 22-04-26 | 23-04-26 | 24-04-24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | -4.25% | -4.06% | 7.28% | 10.1% | 16.7% |
| ROA (Net income/ Total Assets) | - | - | -1.99% | - | 3% | 4.88% | 6.6% |
| Assets 1 | - | - | 3,834 | - | 4,500 | 4,234 | 5,545 |
| Book Value Per Share 2 | - | - | 2.530 | 2.450 | 2.610 | 2.910 | 3.080 |
| Cash Flow per Share 2 | - | - | 0.0800 | -0.2900 | 0.2200 | 0.4300 | 0.6500 |
| Capex 1 | - | - | 40.8 | 82.4 | 43.5 | 106 | - |
| Capex / Sales | - | - | 2.01% | 3.68% | 1.55% | 3.28% | - |
| Announcement Date | 21-04-28 | 22-04-26 | 23-04-26 | 24-04-24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.23
CNY
Average target price
12.7
CNY
Spread / Average Target
+13.09%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +36.62% | 1.07B | |
| +34.35% | 693B | |
| +29.39% | 584B | |
| -3.49% | 372B | |
| +20.15% | 332B | |
| +6.19% | 294B | |
| +14.11% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +9.21% | 168B |
- Stock Market
- Equities
- 600200 Stock
- Financials JiangSu WuZhong Pharmaceutical Development Co., Ltd.
